Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers

Published:2024 Issue: Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Ozawa Risako¹^ORCID,Nishikawa Tadaaki²^ORCID,Yoshida Hiroshi³^ORCID,Shiraishi Kouya⁴^ORCID,Shimoi Tatsunori²^ORCID,Kato Tomoyasu¹^ORCID,Yonemori Kan²^ORCID

Affiliation:

1. Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.

2. Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

3. Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.

4. Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.

Funder

National Cancer Center Research and Development

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e103

Reference39 articles.

1. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

2. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

3. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients

4. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP